<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02060006</url>
  </required_header>
  <id_info>
    <org_study_id>PRO13060453</org_study_id>
    <nct_id>NCT02060006</nct_id>
  </id_info>
  <brief_title>TB-IRIS NSAID Cox-2 Inhibitor Prevention Trial</brief_title>
  <official_title>A Double-Blind Randomized Placebo Controlled Trial for Prevention of Tuberculosis-Immune Reconstitution Inflammatory Syndrome With Non-Steroid Anti-Inflammatory Drugs (NSAIDs) in HIV-Infected Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Stellenbosch</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Stellenbosch</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Non-Steroid Anti-Inflammatory Drugs (NSAIDs) reduce pain and inflammation by
      inhibiting cyclooxygenase, an enzyme in the pathway for formation of prostaglandins and
      thromboxane. Prior studies have proven the role of ibuprofen (an NSAID) in modulating lung
      injury and decreasing pulmonary damage in cystic fibrosis. While there has been an intense
      effort by the scientific community to define the best treatment strategies for tuberculosis
      immune reconstitution inflammatory syndrome (TB-IRIS), to our knowledge there is no available
      study evaluating preventive strategies using anti-inflammatory agents for TB-IRIS, a highly
      morbid complication in HIV-infected TB patients initiating antiretroviral therapy (ART).

      Design and Methods: We propose to conduct a single center double-blind placebo-controlled
      randomized trial to investigate the efficacy of daily self-administered Meloxicam (a NSAID)
      versus placebo for prevention of Tuberculosis associated Immune Reconstitution Inflammatory
      Syndrome (TB-IRIS). A total of 150 HIV-infected adults who are treated for Tuberculosis for
      at least 2 weeks and about to initiate HIV treatment at Brewelskloof Hospital, Worcester, and
      Tygerberg Teaching Hospital, Cape Town, will be randomized to one of the following
      treatments: Meloxicam 7.5 mg tablet once-a-day, the experimental arm, versus Placebo tablet
      once-a-day, the control arm, for 8 weeks. All patients will be followed up for 12 months.
      Primary efficacy outcome: The decrease of the incidence of paradoxical TB IRIS by at least
      20%; Primary safety outcome: The proportion of patients who temporarily or permanently
      discontinue Meloxicam due to any adverse event (e.g. dyspepsia or gastro-intestinal upset).
      Secondary outcomes are: 1) the proportion of patients in each arm with the following
      indicators of TB-IRIS severity/quality of life (QOL) (degree of pain or discomfort &gt;III,
      presence of local or disseminated suppuration/abscess of any site, unscheduled clinic visits,
      hospitalizations, missed more than a day at work, etc; 2) The incidence of other types of
      IRIS (e.g. Kaposi Sarcoma or cryptococcal meningitis).

      This study will provide important and novel data on the feasibility and efficacy of using a
      cheap, widely available NSAID used in both developed and developing countries, as a
      preventive intervention for TB-IRIS that could be quickly put into practice if proven to be
      effective
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2014</start_date>
  <completion_date>April 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of TB IRIS</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion discontinuing Meloxicam due to adverse event</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients in each arm with the following indicators of TB-IRIS severity/quality of life (QOL) (degree of pain or discomfort &gt;III</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with local or disseminated suppuration/abscess of any site, unscheduled clinic visits, hospitalizations, missed more than a day at work, etc</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Placebo 7.5 mg daily for 8 weeks</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 7.5 mg once-daily First 8 weeks of ART Only Control arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Meloxicam 7.5 mg once-daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Meloxicam 7.5mg once-daily for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meloxicam 7.5mg daily for 8 weeks</intervention_name>
    <description>Meloxicam 7.5mg daily for 8 weeks</description>
    <arm_group_label>Meloxicam 7.5 mg once-daily</arm_group_label>
    <other_name>Cox-2 Inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and non-pregnant females age 18 years of age or older

          -  Evidence of HIV-1 infection

          -  TB treatment (&lt;2 weeks) and initiating EFV-based antiretroviral therapy as per the
             South African Department of Health Guidelines

          -  Living in the study site catchment area and having had a known address for more than 3
             months

          -  Written informed consent

        Exclusion Criteria:

          -  History of aspirin sensitivity and allergies to other NSAIDs

          -  Current or recent use (&lt;3 months) of aspirin, NSAIDs, or anticoagulants such as
             warfarin.

          -  Current or recent use of corticosteroid therapy

          -  History of gastro-intestinal bleeding or peptic ulcer

          -  History of cardiovascular thrombotic events (myocardial infarction or stroke),
             hypertension, or congestive heart failure

          -  Severe renal impairment as evidenced by creatinine clearance &lt;50 (Cockcroft- Gault
             Formula)

          -  Severe liver disease (ALT &gt; five times upper limit of normal)

          -  Presence of a medical condition likely to result in death within 6 months from start
             of ART. These conditions include suspected or CNS lymphoma, PMLE and disseminated
             visceral Kaposi's sarcoma

          -  Cognitive disorder(s) that could impair ability to comply with study requirements, as
             determined by the study physician

          -  Karnofsky performance score &lt;60
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jean B Nachega, MD, PhD</last_name>
    <phone>+27 21 938 9933</phone>
    <email>JNACHEGA@SUN.AC.ZA</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stellenbosch University Tygerberg Hospital</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape Province</state>
        <zip>7505</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean B Nachega, MD, PhD</last_name>
      <phone>+27219389933</phone>
      <email>JNACHEGA@SUN.AC.ZA</email>
    </contact>
    <investigator>
      <last_name>Jean B Nachega, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <reference>
    <citation>Eshun-Wilson I, Havers F, Nachega JB, Prozesky HW, Taljaard JJ, Zeier MD, Cotton M, Simon G, Soentjens P. Evaluation of paradoxical TB-associated IRIS with the use of standardized case definitions for resource-limited settings. J Int Assoc Physicians AIDS Care (Chic). 2010 Mar-Apr;9(2):104-8. doi: 10.1177/1545109710361537. Epub 2010 Feb 16.</citation>
    <PMID>20160249</PMID>
  </reference>
  <reference>
    <citation>Meintjes G, Wilkinson RJ, Morroni C, Pepper DJ, Rebe K, Rangaka MX, Oni T, Maartens G. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS. 2010 Sep 24;24(15):2381-90. doi: 10.1097/QAD.0b013e32833dfc68.</citation>
    <PMID>20808204</PMID>
  </reference>
  <reference>
    <citation>Meintjes G, Lawn SD, Scano F, Maartens G, French MA, Worodria W, Elliott JH, Murdoch D, Wilkinson RJ, Seyler C, John L, van der Loeff MS, Reiss P, Lynen L, Janoff EN, Gilks C, Colebunders R; International Network for the Study of HIV-associated IRIS. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis. 2008 Aug;8(8):516-23. doi: 10.1016/S1473-3099(08)70184-1.</citation>
    <PMID>18652998</PMID>
  </reference>
  <reference>
    <citation>Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, Gengiah T, Nair G, Bamber S, Singh A, Khan M, Pienaar J, El-Sadr W, Friedland G, Abdool Karim Q. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010 Feb 25;362(8):697-706. doi: 10.1056/NEJMoa0905848.</citation>
    <PMID>20181971</PMID>
  </reference>
  <reference>
    <citation>Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E, Madec Y, Marcy O, Chan S, Prak N, Kim C, Lak KK, Hak C, Dim B, Sin CI, Sun S, Guillard B, Sar B, Vong S, Fernandez M, Fox L, Delfraissy JF, Goldfeld AE; CAMELIA (ANRS 1295–CIPRA KH001) Study Team. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011 Oct 20;365(16):1471-81. doi: 10.1056/NEJMoa1013911.</citation>
    <PMID>22010913</PMID>
  </reference>
  <reference>
    <citation>Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, Luetkemeyer AF, Hogg E, Rooney JF, Wu X, Hosseinipour MC, Lalloo U, Veloso VG, Some FF, Kumarasamy N, Padayatchi N, Santos BR, Reid S, Hakim J, Mohapi L, Mugyenyi P, Sanchez J, Lama JR, Pape JW, Sanchez A, Asmelash A, Moko E, Sawe F, Andersen J, Sanne I; AIDS Clinical Trials Group Study A5221. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011 Oct 20;365(16):1482-91. doi: 10.1056/NEJMoa1013607.</citation>
    <PMID>22010914</PMID>
  </reference>
  <reference>
    <citation>Konstan MW, Schluchter MD, Xue W, Davis PB. Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis. Am J Respir Crit Care Med. 2007 Dec 1;176(11):1084-9. Epub 2007 Sep 13.</citation>
    <PMID>17872492</PMID>
  </reference>
  <reference>
    <citation>Kvale D, Ormaasen V, Kran AM, Johansson CC, Aukrust P, Aandahl EM, Frøland SS, Taskén K. Immune modulatory effects of cyclooxygenase type 2 inhibitors in HIV patients on combination antiretroviral treatment. AIDS. 2006 Apr 4;20(6):813-20.</citation>
    <PMID>16549964</PMID>
  </reference>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2014</study_first_submitted>
  <study_first_submitted_qc>February 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2014</study_first_posted>
  <last_update_submitted>April 2, 2014</last_update_submitted>
  <last_update_submitted_qc>April 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Stellenbosch</investigator_affiliation>
    <investigator_full_name>Prof Jean Nachega</investigator_full_name>
    <investigator_title>Professor Extraordinary</investigator_title>
  </responsible_party>
  <keyword>TB</keyword>
  <keyword>IRIS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Immune Reconstitution Inflammatory Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meloxicam</mesh_term>
    <mesh_term>Cyclooxygenase 2 Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

